During cycle 4 of pola-R-CHP, a patient develops grade 2 peripheral neuropathy. What is the most appropriate initial management? A. Discontinue polatuzumab permanently B. Initiate duloxetine and continue polatuzumab at full dose C. Hold polatuzumab until grade ≤1 then resume at 1.4 mg/kg D. Switch polatuzumab vedotin to vincristine
Take the next step with this assignment
Every order includes a free originality report, unlimited revisions and 24/7 human support.
- Subject expert matched to your exact course
- Original work, written from scratch for you
- On-time delivery, with free revisions
Purchase This Solution
Order a Custom Written Paper
Secure checkout · Confidential service · No reselling
[Solved]: During cycle 4 of pola-R-CHP, a patient…